A detailed history of Quent Capital, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Quent Capital, LLC holds 256 shares of BMRN stock, worth $16,235. This represents 0.0% of its overall portfolio holdings.

Number of Shares
256
Previous 391 34.53%
Holding current value
$16,235
Previous $32,000 46.88%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

SELL
$69.02 - $93.84 $9,317 - $12,668
-135 Reduced 34.53%
256 $17,000
Q2 2024

Jul 08, 2024

BUY
$74.43 - $92.22 $10,792 - $13,371
145 Added 58.94%
391 $32,000
Q1 2024

May 02, 2024

SELL
$83.81 - $99.0 $9,386 - $11,088
-112 Reduced 31.28%
246 $21,000
Q4 2023

Jun 14, 2024

BUY
$76.22 - $98.51 $1,753 - $2,265
23 Added 6.87%
358 $34,000
Q4 2023

Jan 19, 2024

BUY
$76.22 - $98.51 $1,753 - $2,265
23 Added 6.87%
358 $34,000
Q3 2023

Jun 14, 2024

SELL
$85.07 - $94.48 $104,040 - $115,549
-1,223 Reduced 78.5%
335 $29,000
Q3 2023

Oct 10, 2023

SELL
$85.07 - $94.48 $104,040 - $115,549
-1,223 Reduced 78.5%
335 $29,000
Q2 2023

Jun 14, 2024

BUY
$86.68 - $100.3 $1,993 - $2,306
23 Added 1.5%
1,558 $135,000
Q2 2023

Jul 10, 2023

BUY
$86.68 - $100.3 $1,993 - $2,306
23 Added 1.5%
1,558 $135,000
Q1 2023

Jun 14, 2024

BUY
$87.74 - $117.27 $113,096 - $151,161
1,289 Added 523.98%
1,535 $149,000
Q1 2023

Apr 05, 2023

BUY
$87.74 - $117.27 $120,554 - $161,128
1,374 Added 853.42%
1,535 $149,000
Q3 2022

Nov 10, 2022

BUY
$82.16 - $96.94 $985 - $1,163
12 Added 8.05%
161 $14,000
Q1 2022

May 12, 2022

BUY
$74.28 - $92.69 $2,228 - $2,780
30 Added 25.21%
149 $11,000
Q4 2021

May 12, 2022

BUY
$71.72 - $91.47 $2,797 - $3,567
39 Added 48.75%
119 $11,000
Q4 2021

Feb 28, 2022

BUY
$71.72 - $91.47 $5,737 - $7,317
80 New
80 $7,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Quent Capital, LLC Portfolio

Follow Quent Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quent Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quent Capital, LLC with notifications on news.